Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [14C] PF-07976016
PF-07976016 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-07976016 Dose 1 | EXPERIMENTAL | - |
| PF-07976016 Dose 2 | EXPERIMENTAL | - |
| PF-07976016 Dose 3 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-07976016 | DRUG | Taken once daily |
| Placebo | DRUG | Taken once daily |
Key Inclusion Criteria: * Male or non-pregnant, non-breastfeeding female, 18 to 74 years of age at Visit 1 * Body Mass Index ≥30.0 kg/m2 at Visit 1, with stable body weight, defined as \<5 kg change in the 12 weeks before Visit 1 * Eligible and willing to receive required background medicine * Will...
Top 20 of 35 competitors
PF-07976016 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE) for the treatment of obesity. It is in Phase 2 clinical development and has been studied in a completed Phase 2 trial. It is not yet approved for any indication.
PF-07976016 is being developed for the treatment of obesity in adults. The Phase 2 trial enrolled adults aged 18 years and older with obesity. It is investigational and has not been approved for use in obesity or any other condition.
PF-07976016 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the clinical program evaluating this small molecule in obesity.
PF-07976016 is in Phase 2 clinical development. One Phase 2 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not received regulatory approval.
PF-07976016 has been evaluated in one Phase 2 trial, NCT06717425, titled A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity. The trial was completed, enrolled 263 participants, and was randomized, double-blind, and placebo-controlled, with sites in the United States, Canada, and Poland.
Yes, [14C] PF-07976016 is an alternative name for PF-07976016. The carbon-14 label is used in certain studies, but both refer to the same investigational small molecule being developed by Pfizer for obesity.